Center-Authored Papers

Filters: Author is London, Wendy B  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
RISK
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Peripheral Blood Stem Cell Transplantation
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
October 2013
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Neuroblastoma
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
natural killer cells
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
MHC class I
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
KIR-ligand
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
KIR
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
July 2014
Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM et al..  2014.  Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.. Molecular oncology. 8(3):669-78. Abstract
Infant
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Immunomagnetic Separation
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Humans
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
HLA-Bw4
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
HLA
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
Disease-Free Survival
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Clinical Research Division
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look TA et al..  2013.  Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group.. Cancer. Abstract
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL et al..  2014.  Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project.. Pediatric blood & cancer. Abstract
Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM et al..  2014.  Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.. Molecular oncology. 8(3):669-78. Abstract
Child, Preschool
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
Child
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
cancer immunotherapy
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
August 2014
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL et al..  2014.  Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project.. Pediatric blood & cancer. Abstract
August 2013
Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look TA et al..  2013.  Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group.. Cancer. Abstract
Adult
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract